[ET Net News Agency, 31 October 2024] UBS raised the target price for RemeGen (09995) to
HKD22.6 from HKD20.2 and maintained the "buy" rating.
The research house said based on Q324 results and regulatory progress, it revises up
2025/26 revenue forecasts by 1.9%/1.6%, and revises down R&D/selling expense ratio by
1/1ppt and 10/5ppt, respectively. (rc)